Spruce Biosciences Operating Income Over Time
| SPRB Stock | USD 59.05 0.83 1.43% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Spruce Biosciences Performance and Spruce Biosciences Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Spruce Biosciences. If investors know Spruce will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Spruce Biosciences assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Earnings Share (84.32) | Revenue Per Share | Quarterly Revenue Growth (0.76) | Return On Assets | Return On Equity |
Understanding Spruce Biosciences Common requires distinguishing between market price and book value, where the latter reflects Spruce's accounting equity. The concept of intrinsic value - what Spruce Biosciences' is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push Spruce Biosciences' price substantially above or below its fundamental value.
Please note, there is a significant difference between Spruce Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Spruce Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. In contrast, Spruce Biosciences' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Operating Income Analysis
Compare Spruce Biosciences Common and related stocks such as NRX Pharmaceuticals, Werewolf Therapeutics, and OUTLOOK THERAPEUTICS INC Operating Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| NRXP | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (134.5 K) | (1 M) | (713.2 K) | (22.1 M) | (95.2 M) | (44.3 M) | (27.6 M) | (19.7 M) | (17.7 M) | (18.6 M) |
| HOWL | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (22.4 M) | (50.1 M) | (56.1 M) | (40.5 M) | (73.6 M) | (66.2 M) | (69.5 M) |
| OTLK | (12.4 M) | (12.4 M) | (12.4 M) | (12.4 M) | (46.6 M) | (51.3 M) | (35.9 M) | (29.6 M) | (36.3 M) | (36.8 M) | (51.7 M) | (63.1 M) | (53.1 M) | (71.7 M) | (67.1 M) | (60.4 M) | (63.4 M) |
| IOBT | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (9.9 M) | (10.1 M) | (41.2 M) | (71.4 M) | (91.4 M) | (95.2 M) | (85.7 M) | (81.4 M) |
| CUE | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (1.9 M) | (7.7 M) | (23.2 M) | (38.7 M) | (36.8 M) | (45 M) | (43.7 M) | (53.2 M) | (52.1 M) | (41.5 M) | (37.4 M) | (39.2 M) |
| OSTX | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (5.6 K) | (4.8 M) | (4.4 M) | (4.3 M) | (6.8 M) | (6.1 M) | (6.4 M) |
| VTVT | (35.8 M) | (35.8 M) | (35.8 M) | (35.8 M) | (28.9 M) | (38.1 M) | (55 M) | (50.7 M) | (19.8 M) | (20.9 M) | (11.9 M) | (21.7 M) | (22.5 M) | (25.5 M) | (24.2 M) | (27.8 M) | (29.2 M) |
| EQ | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (1.7 M) | (8.6 M) | (26.7 M) | (29.5 M) | (37.8 M) | (62.1 M) | (14.5 M) | (8.3 M) | (7.4 M) | (7.8 M) |
| COEP | (10.1 K) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (6.9 M) | (14 M) | (34.2 M) | (21.5 M) | (10.1 M) | (9 M) | (9.5 M) |
Spruce Biosciences Common and related stocks such as NRX Pharmaceuticals, Werewolf Therapeutics, and OUTLOOK THERAPEUTICS INC Operating Income description
Operating Income is the amount of profit realized from Spruce Biosciences Common operations after accounting for operating expenses such as cost of goods sold (COGS), wages and depreciation. Operating income takes the gross income and subtracts other operating expenses and then removes depreciation. Operating Income of Spruce Biosciences Common is typically a synonym for earnings before interest and taxes (EBIT) and is also commonly referred to as operating profit or recurring profit. Earnings before interest and taxes (EBIT), representing the amount of profit a company generates from its operations.My Equities
My Current Equities and Potential Positions
| Spruce Biosciences Common | SPRB |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | 611 Gateway Boulevard, |
| Exchange | NASDAQ Exchange |
USD 59.05
Check out Spruce Biosciences Performance and Spruce Biosciences Correlation. You can also try the ETFs module to find actively traded Exchange Traded Funds (ETF) from around the world.
Spruce Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.